

Biosimilars in Inflammatory bowel disease: A review of post-marketing experienc



全部 图片 视频 新闻 地图 图书

找到约 34,700 条结果

时间不限

- 过去 1 小时内
- 过去 24 小时内
- 过去 1 周内
- 过去 1 个月内
- 过去 1 年内

所有结果

精确匹配

[Google 学术: Biosimilars in Inflammatory bowel disease: A review of post-marketing experience](#)

[... \) and Italian Group of Inflammatory Bowel Disease \(IG- ... - Fiorino - 被引用次数: 39](#)

[... the long-term efficacy of infliximab in Crohn's disease - Baert - 被引用次数: 1700](#)

[Review article: biosimilars are the next generation of ... - Rinaudo - Gaujous - 被引用次数: 42](#)

[Clinical experience with infliximab biosimilar Remsima \(CT ... - NCBI](#)

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4830106/>

21 Mar 2016 ... Until now the number of patients with **inflammatory bowel disease** ... and reliable **postmarketing** pharmacovigilance is therefore required in the coming years. ... This **review** will focus on the efficacy and safety of CT-P13 in IBD ...

[Biosimilars in IBD: from theory to practice : Nature Reviews ...](#)

[www.nature.com/nrgastro/journal/vaop/ncurrent/.../nrgastro.2016.155.html](http://www.nature.com/nrgastro/journal/vaop/ncurrent/.../nrgastro.2016.155.html)

12 Oct 2016 ... Importantly for patients with IBD, CT-P13 was the first **biosimilar** to infliximab ... **biosimilar** to infliximab receiving marketing authorization in Europe. ... **Post- marketing** study of **biosimilar** infliximab (CT-P13) to evaluate its ... therapy in **Crohn's disease** and ulcerative colitis – **experiences** from a single center.

[Future directions in inflammatory bowel disease management](#)

[www.sciencedirect.com/science/article/pii/S1873994614000944](http://www.sciencedirect.com/science/article/pii/S1873994614000944)

16 Apr 2014 ... Clinical management of **inflammatory bowel diseases (IBD)**, new treatment ... In September 2013, the first infliximab **biosimilar** was approved by the ... depend on additional clinical and **post-marketing surveillance** data. ... For example, in a recent landmark meta-**analysis** of genome-wide **studies** followed by ...

[\[PDF\] Medical Review\(s\) - FDA](#)

[www.accessdata.fda.gov/drugsatfda\\_docs/.../125544Orig1s000MedR.pdf](http://www.accessdata.fda.gov/drugsatfda_docs/.../125544Orig1s000MedR.pdf)

**Name of journal:** *World Journal of Gastroenterology*

**ESPS Manuscript NO:** 29937

**Manuscript Type:** MINIREVIEWS

**Biosimilars in Inflammatory bowel disease: A review of post-marketing experience**

Simona Deiana, Tommaso Gabbani, Vito Annese

### Abstract

Biologic compounds are obtained from living organisms or cell cultures by means of biotechnology methods. A similar biologic drug, commonly called biosimilar, is a product copied by a native approved biologic drug whose license has expired. Biosimilar drugs usually are marketed at a lower price and provide important financial savings for public healthcare systems. Some differences between biosimilars and original biologic drugs might exist but they are acceptable if they fall within defined "boundaries of tolerance": differences in some features between the two molecules are considered important only if

### Match Overview

1	<b>Crossref</b> 95 words Park, Dong Il. "Current status of biosimilars in the treatment of inflammatory bowel diseases", <i>Intestinal Research</i>	3%
2	<b>Crossref</b> 73 words Gecse, Krisztina B., Barbara D. Lovász, Klaudia Farkas, János Banai, László Bene, Beáta Gasztonyi, Petra Anna	2%
3	<b>Crossref</b> 70 words Braun, Jürgen, and Alex Kudrin. "Switching to biosimilars: Evidence of clinical safety, effectiveness of infliximab (CT-P13): Evidence of clinical safety, effectiveness"	2%
4	<b>Internet</b> 57 words crawled on 23-Nov-2016 <a href="http://www.dovepress.com">www.dovepress.com</a>	2%
5	<b>Crossref</b> 43 words Isaacs, J. D., M. Cutolo, E. C. Keystone, W. Park, and J. Braun. "Biosimilars in immune-mediated inflammatory diseases"	1%
6	<b>Internet</b> 37 words crawled on 15-Nov-2016 <a href="http://clinicaltrials.gov">clinicaltrials.gov</a>	1%
7	<b>Internet</b> 35 words crawled on 10-Dec-2016 <a href="http://www.health.gov.au">www.health.gov.au</a>	1%
8	<b>Internet</b> 33 words crawled on 10-Jul-2016 <a href="http://www.ncbi.nlm.nih.gov">www.ncbi.nlm.nih.gov</a>	1%

[全部](#) [图片](#) [视频](#) [新闻](#) [地图](#) [图书](#)

找到约 34,700 条结果

**时间不限**

过去 1 小时内  
过去 24 小时内  
过去 1 周内  
过去 1 个月内  
过去 1 年内

**所有结果**

精确匹配

[Google 学术: Biosimilars in Inflammatory bowel disease: A review of post-marketing experience](#)

[...](#) and Italian Group of Inflammatory Bowel Disease (IG-... - Fiorino - 被引用次数: 39

[... the long-term efficacy of infliximab in Crohn's disease](#) - Baert - 被引用次数: 1700

[Review article: biosimilars are the next generation of ...](#) - Rinaudo - Gaujous - 被引用次数: 42

[Clinical experience with infliximab biosimilar Remsima \(CT ... - NCBI](#)

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4830106/>

21 Mar 2016 ... Until now the number of patients with **inflammatory bowel disease** ... and reliable **postmarketing** pharmacovigilance is therefore required in the coming years. ... This **review** will focus on the efficacy and safety of CT-P13 in IBD ...

[Biosimilars in IBD: from theory to practice : Nature Reviews ...](#)

[www.nature.com/nrgastro/journal/vaop/ncurrent/.../nrgastro.2016.155.html](http://www.nature.com/nrgastro/journal/vaop/ncurrent/.../nrgastro.2016.155.html)

12 Oct 2016 ... Importantly for patients with IBD, CT-P13 was the first **biosimilar** to infliximab ... **biosimilar** to infliximab receiving marketing authorization in Europe. ... **Post-marketing** study of **biosimilar** infliximab (CT-P13) to evaluate its ... therapy in **Crohn's disease** and ulcerative colitis – **experiences** from a single center.

[Future directions in inflammatory bowel disease management](#)

[www.sciencedirect.com/science/article/pii/S1873994614000944](http://www.sciencedirect.com/science/article/pii/S1873994614000944)

16 Apr 2014 ... Clinical management of **inflammatory bowel diseases** (IBD), new treatment ... In September 2013, the first infliximab **biosimilar** was approved by the ... depend on additional clinical and **post-marketing surveillance** data. ... For example, in a recent landmark **meta-analysis** of genome-wide **studies** followed by ...

[\[PDF\] Medical Review\(s\) - FDA](#)

[www.accessdata.fda.gov/drugsatfda\\_docs/.../125544Orig1s000MedR.pdf](http://www.accessdata.fda.gov/drugsatfda_docs/.../125544Orig1s000MedR.pdf)

5 Apr 2016 ... **Post-marketing** ... **studies** ... **studies** ... **studies** ...

[全部](#)[新闻](#)[图片](#)[视频](#)[更多](#)[设置](#)[工具](#)

找到约 25,300 条结果 (用时 0.82 秒)

## Google 学术 : Biosimilars in inflammatory bowel disease: A review of post-marketing experience

... ), and Italian Group of Inflammatory Bowel Disease (IG- ... - Fiorino - 被引用次数 : 39

... the long-term efficacy of infliximab in Crohn's disease - Baert - 被引用次数 : 1718

Review article: biosimilars are the next generation of ... - Rinaudo-Gaujous - 被引用次数 : 43

## Biosimilars in Inflammatory Bowel Disease: Facts and Fears of ...

[www.sciencedirect.com/science/article/pii/S1542356516302129](http://www.sciencedirect.com/science/article/pii/S1542356516302129) - 翻译此页

作者 : S Ben-Horin - 2016 - 被引用次数 : 3 - 相关文章

2016年5月21日 - Biosimilar;; Extrapolation;; Inflammatory Bowel Disease;; CT-P13;; Infliximab;; Infliximab-dyyb ... In this review, we consider the fears and facts regarding .... After approval, does the evidence from post-marketing surveillance ...

## Clinical experience with infliximab biosimilar Remsima (CT-P13) in ...

[https://www.ncbi.nlm.nih.gov/NCBI/Literature/PubMedCentral\(PMC\)](https://www.ncbi.nlm.nih.gov/NCBI/Literature/PubMedCentral(PMC)) - 翻译此页

作者 : J Jahnsen - 2016 - 被引用次数 : 3 - 相关文章

2016年3月21日 - This review will focus on the efficacy and safety of CT-P13 in IBD .... with IBD in South Korea a postmarketing study was conducted [Park et al.

## Efficacy, Safety and Immunogenicity of Biosimilars in Inflammatory ...

<https://www.ncbi.nlm.nih.gov/labs/articles/27758715/> - 翻译此页

2016年10月14日 - ... of Biosimilars in Inflammatory Bowel Diseases: A Systematic Review ... Large prospective post-marketing studies are needed to assess the ...

## The Role of Biosimilars in Inflammatory Bowel Disease

[www.gastroenterologyandhepatology.net/.../the-role-of-biosimilars-in-infla...](http://www.gastroenterologyandhepatology.net/.../the-role-of-biosimilars-in-infla...) - 翻译此页

2016年12月8日 - Infliximab biosimilars for the treatment of IBD have been available in Europe .... phase 4 postmarketing surveillance takes on greater significance, and in ... A survey of 307